26–31 May 2024
Western University
America/Toronto timezone
Welcome to the 2024 CAP Congress Program website! / Bienvenue au siteweb du programme du Congrès de l'ACP 2024!

Session

(DPMB/DAPI) W3-6 Medical Imaging III | Imagerie médicale III (DPMB/DPAE)

W3-6
29 May 2024, 13:30
Western University

Western University

Presentation materials

There are no materials yet.

  1. Xiaoxiao Li (Electrical and Computer Engineering, The University of British Columbia)
    29/05/2024, 13:30
    Physics in Medicine and Biology / Physique en médecine et en biologie (DPMB-DPMB)
    Invited Speaker / Conférencier(ère) invité(e)

    The challenges posed by small and heterogeneous medical datasets significantly impede AI development in biomedical data analysis. My research addresses this issue by utilizing innovative partially personalized federated learning frameworks. These frameworks facilitate collaborative learning across multiple medical centers, enhancing the development of precise, personalized AI models. In this...

    Go to contribution page
  2. April Khademi (TMU Electrical, Computer, and Biomedical Engineering)
    29/05/2024, 14:15
    Symposia Day (DPMB/DAPI - DPMB/DPAI) - Medical Imaging / Imagerie médicale
    Invited Speaker / Conférencier(ère) invité(e)

    Medical images play a critical role in patient management and are used to decide treatment; they also comprise nearly 80% of all hospital data. We have an opportunity to leverage AI in medical imaging, to change the way medicine is practiced. AI tools for medical imaging can offer more accurate diagnosis, improve inter-rater agreement across specialists, and reduce turn-around-time -- all...

    Go to contribution page
  3. Logan Mackay (TRIUMF / University of Edinburgh)
    29/05/2024, 14:45
    Symposia Day (DPMB/DAPI - DPMB/DPAI) - Medical Imaging / Imagerie médicale
    Oral not-in-competition (Undergraduate Student) / Orale non-compétitive (Étudiant(e) du 1er cycle)

    Targeted Alpha Therapy (TAT) is a mode of cancer treatment in which alpha-emitting radionuclides attached to selective delivery molecules are injected into patients to preferentially kill cancer cells, a promising candidate radionuclide is actinium-225. Due to the relatively low radio-activities used (MBq’s) in this treatment and the absence of positron emissions in actinium-225’s decay chain,...

    Go to contribution page
Building timetable...